InvestorsHub Logo
Followers 283
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: Steges post# 101103

Thursday, 04/03/2014 5:46:56 PM

Thursday, April 03, 2014 5:46:56 PM

Post# of 410689

The value accretion curve in pharmaceuticals is very high, and what that means is that the difference in value between licensing a product that has completed Phase I versus licensing a product that has completed Phase III or has an NDA already filed, is logarithmic. The value of a product accretes very rapidly once it gets into human clinical trials.


We have two opioid abuse deterrent products, ELI-200 and ELI-201, in human trials and an additional five abuse deterrent formulations under active development.

Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News